Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pars Plana Vitrectomy Clear all
Completed Not applicable Interventional

A Study to Evaluate the Safety and Performance of the Vista Probe for Vitrectomy Surgery

NCT05689333
View directory record Official record
Conditions
Vitrectomy
Interventions
Vista Vitrectomy Probe
Device
Lead sponsor
VISTA Ophthalmics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Bradenton, Florida • Bala-Cynwyd, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

NCT01229410
View directory record Official record
Conditions
Vitrectomy
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2013 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

27-gauge Vitrectomy Wound Integrity: a Prospective, Randomized Trial Comparing Angled Versus Straight Entry

NCT02836210
View directory record Official record
Conditions
Epiretinal Membrane
Interventions
27-gauge vitrectomy wound construction
Device
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Aflibercept Injection for Proliferative Diabetic Retinopathy

NCT01805297
View directory record Official record
Conditions
Vitreous Hemorrhage
Interventions
Intravitreal Aflibercept Injection, Standard Vitrectomy
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 19, 2026, 2:42 AM EDT
Terminated Not applicable Interventional

Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

NCT01410201
View directory record Official record
Conditions
Epiretinal Membrane, Macular Edema
Interventions
Dexamethasone Intravitreal Implant
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Chesterfield, Missouri • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis

NCT00609687
View directory record Official record
Conditions
Sarcoidosis-associated Ocular Inflammation
Interventions
Diagnostic Vitrectomy
Procedure
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Sep 19, 2026, 2:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intravitreal Injection Site and Perceived Pain

NCT05640895
View directory record Official record
Conditions
Pain
Interventions
Intravitreal injection site
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 19, 2026, 2:42 AM EDT
Terminated Phase 1 Interventional

SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy

NCT00936520
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Pars Plana Vitrectomy
Interventions
SAR 1118 0.1%, SAR 1118 1.0%, SAR 1118 5.0%
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy

NCT01257698
View directory record Official record
Conditions
Macular Hole, Retinal Detachment
Interventions
Dorzolamide 2%-timolol 0.5% topical eyedrops
Drug
Lead sponsor
Mid Atlantic Retina
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 19, 2026, 2:42 AM EDT
Completed No phase listed Observational

Inflammasomes in Cell Death in FTMH, ERM, and RRD

NCT03332758
View directory record Official record
Conditions
Retinal Detachment, Full Thickness Macular Hole, Epiretinal Membrane
Interventions
Pars plana vitrectomy, External drainage
Procedure
Lead sponsor
Allen C. Ho, MD
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma

NCT01460810
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
1000CsK Silicon Oil Tamponade
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 19, 2026, 2:42 AM EDT
Completed No phase listed Observational

Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.

NCT01809093
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus
Interventions
Blood draw
Biological
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Minutes and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes

NCT02477605
View directory record Official record
Conditions
Vitreoretinal Disease
Interventions
CONSTELLATION® 27-gauge Combined Surgical Pak, CONSTELLATION® 23-gauge Combined Surgical Pak, Vitrectomy surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
22 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)

NCT01613716
View directory record Official record
Conditions
Diabetic Macular Edema, Epiretinal Membrane
Interventions
Ozurdex
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Not applicable Interventional

23 Gauge and 20 Gauge Vitrectomy for Rhegmatogenous Retinal Detachments

NCT01716507
View directory record Official record
Conditions
Retinal Detachment
Interventions
Retinal Detachment repair
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Sep 19, 2026, 2:42 AM EDT
Recruiting Not applicable Interventional

Head Positioning After Retina Detachment Repair

NCT03714503
View directory record Official record
Conditions
Retina; Detachment, Rhegmatogenous
Interventions
Retina re-attachment repair using C3F8 gas tamponade
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Prairie Village, Kansas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

NCT04136366
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure
Drug · Other
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 19, 2026, 2:42 AM EDT
Completed No phase listed Observational Results available

Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy

NCT01319318
View directory record Official record
Conditions
Vitrectomy
Interventions
Pars Plana Vitrectomy
Procedure
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 19, 2026, 2:42 AM EDT
Enrolling by invitation Phase 4 Interventional

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

NCT06191094
View directory record Official record
Conditions
Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Interventions
Faricimab Injection, sham treatment
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Not applicable Interventional

The Post-Vitrectomy Lenstatin™ Study

NCT02131194
View directory record Official record
Conditions
Cataract, Nuclear Progressive
Interventions
Lenstatin, Placebo
Dietary Supplement · Drug
Lead sponsor
Lenstatin LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 19, 2026, 2:42 AM EDT
Not listed Early Phase 1 Interventional

Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%

NCT06539637
View directory record Official record
Conditions
Cataract
Interventions
OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}, Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop
Combination Product · Other
Lead sponsor
DHS Consulting
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Westbury, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 19, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

NCT07174726
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa (XLRP)
Interventions
Adeno-associated virus vector expressing a human RPGR gene
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
12 Years to 50 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 19, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Oral Versus Intravenous Sedation for Ocular Procedures

NCT03246724
View directory record Official record
Conditions
Surgery, Sedation
Interventions
Triazolam, Midazolam, Microcrystalline Cellulose, Sodium chloride 0.9%
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 19, 2026, 2:42 AM EDT